A pilot clinical trial was conducted to assess tremelimumab, an mAB that binds CTLA-4, combined with TACE, RFA, or chemoablation in 32 patients with Barcelona Clinic Liver Cancer stage B HCC [247]. Here, CTLA4 is linked to hepatocellular carcinoma.